9 August 2019

Verona Pharma plc: PDMR Dealing

LONDON, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 8, 2019, Dr. David Ebsworth, Chairman of the Company, purchased a further 60,000 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 50 pence per Ordinary Share and a total purchase price of £30,000.  This purchase brings the total purchases made by Dr. Ebsworth during 2019 to approximately £80,000.

Following the acquisition, Dr. Ebsworth will have an interest in the Company of 295,387 Ordinary Shares, representing 0.28% of the Company’s issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name David Ebsworth
2 Reason for the notification
a) Position/status Chairman
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Verona Pharma plc
b) LEI 213800EVI6O6J3TIAL06


4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
a) Description of the financial instrument, type of instrument Ordinary Shares of 5 pence each 
  Identification code GB00BYW2KH80 
b) Nature of the transaction David Ebsworth purchased 60,000 Ordinary Shares 
c) Price(s) and volume(s) Price(s) Volume(s)
    50 pence per Ordinary Share 60,000 Ordinary Shares
d) Aggregated information N/A  
  -  Aggregated volume    
  -  Price    
e) Date of the transaction 8 August 2019 
f) Place of the transaction London Stock Exchange, AIM 

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
N+1 Singer
(Nominated Adviser and UK Broker)
Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer / Iqra Amin (Corporate Finance)  
Mia Gardner (Corporate Broking)  

For further information please contact:


Verona Pharma plc
Jan-Anders Karlsson, CEO
Victoria Stewart, Director of Communications
Tel: +44 (0)20 3283 4200

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)
Brough Ransom /Mia Gardner (Corporate Broking)
Tel: +44 (0)20 3283 4200



Optimum Strategic Communications
(European Media and Investor enquiries)
Mary Clark, Annemarieke Ezendam
Hollie Vile
Tel: +44 (0) 203 950 9144

Argot Partners (Investor enquiries)
Stephanie Marks
Tel. +1 646 644 9590


Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us